VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
IPO Year: 2021
Exchange: NASDAQ
Website: vectivbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2022 | $18.00 | Buy | Jefferies |
| 7/1/2022 | $23.00 | Overweight | Piper Sandler |
Jefferies initiated coverage of VectivBio with a rating of Buy and set a new price target of $18.00
Piper Sandler initiated coverage of VectivBio with a rating of Overweight and set a new price target of $23.00
SVB Leerink initiated coverage of VectivBio Holding with a rating of Outperform and set a new price target of $28.00
SVB Leerink initiated coverage of VectivBio Holding with a rating of Overweight and set a new price target of $28.00
Credit Suisse initiated coverage of VectivBio with a rating of Outperform and set a new price target of $24.00
BofA Securities initiated coverage of VectivBio with a rating of Buy and set a new price target of $19.00